Research

Using the intraoperative hand held probe without lymphoscintigraphy or using only dye correlates with higher sensory morbidity following sentinel lymph node biopsy in breast cancer: A review of the literature

Suk Chul Kim1, Dong Wook Kim1, Renee M Moadel2, Chun K Kim1, Samprit Chatterjee3, Michail K Shafir4, Arlene Travis1, Josef Machac1 and Borys R Krynyckyi*1

Address: 1Department of Radiology, Division of Nuclear Medicine, The Mount Sinai School of Medicine, The Mount Sinai Hospital, New York, New York, USA, 2Department of Nuclear Medicine, Albert Einstein College of Medicine of Yeshiva University, and the Montefiore Medical Center, Bronx, New York, USA, 3Department of Health Policy, The Mount Sinai School of Medicine, The Mount Sinai Hospital, New York, New York, USA and 4Department of Surgery, The Mount Sinai School of Medicine, The Mount Sinai Hospital, New York, New York, USA

Email: Suk Chul Kim - sukchulkim@gmail.com; Dong Wook Kim - mdwook@empas.com; Renee M Moadel - rmoadel@montefiore.org; Chun K Kim - chun.kim@msnynhealth.org; Samprit Chatterjee - samprit.chatterjee@msnyuhealth.org; Michail K Shafir - michail.shafir@msnyuhealth.org; Arlene Travis - arlene.travis@mssm.edu; Josef Machac - josef.machac@mssm.edu; Borys R Krynyckyi* - syrob@msn.com

* Corresponding author

Published: 29 September 2005

Received: 28 July 2005

Accepted: 29 September 2005

World Journal of Surgical Oncology 2005, 3:64 doi:10.1186/1477-7819-3-64

This article is available from: http://www.wjso.com/content/3/1/64

© 2005 Kim et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: There are no studies that have directly investigated the incremental reduction in sensory morbidity that lymphoscintigraphy images (LS) and triangulated body marking or other skin marking techniques provide during sentinel lymph node biopsy (SLNB) compared to using only the probe without LS and skin marking or using only dye. However, an indirect assessment of this potential for additional sensory morbidity reduction is possible by extracting morbidity data from studies comparing the morbidity of SLNB to that of axillary lymph node dissection.

Methods: A literature search yielded 13 articles that had data on sensory morbidity at specific time points on pain, numbness or paresthesia from SLNB that used radiotracer and probe or used only dye as a primary method of finding the sentinel node (SN). Of these, 10 utilized LS, while 3 did not utilize LS. By matching the data in studies not employing LS to the studies that did, comparisons regarding the percentage of patients experiencing pain, numbness/paresthesia after SLNB could be reasonably attempted at a cutoff of 9 months.

Results: In the 7 studies reporting on pain after 9 months (> 9 months) that used LS (1347 patients), 13.8% of patients reported these symptoms, while in the one study that did not use LS (143 patients), 28.7% of patients reported these symptoms at > 9 months (P < 0.0001). In the 6 studies reporting on numbness and/or paresthesia at > 9 months that used LS (601 patients), 12.5% of patients reported these symptoms, while in the 3 studies that did not use LS (229 patients), 23.1% of patients reported these symptoms at > 9 months (P = 0.0002). Similar trends were also noted for all these symptoms at ≤ 9 months.

Conclusion: Because of variations in techniques and time of assessing morbidity, direct comparisons between studies are difficult. Nevertheless at a minimum, a clear trend is present: having the LS images and skin markings to assist during SLNB appears to yield more favorable morbidity outcomes for the patients compared to performing SLNB with only the probe or performing SLNB with dye alone. These results are extremely pertinent, as the main reason for performing SLNB itself in the first place is to achieve reduced morbidity.
Background

There is a trend towards minimally invasive surgery in all aspects of breast cancer management. In keeping with this trend is the increasing popularity of sentinel lymph node biopsy (SLNB), which has been shown to result in lower levels of morbidity in the staging of patients with breast cancer as compared to conventional axillary lymph node dissection (ALND) [1-20]. Therefore, it has essentially become the standard of care [21]. Furthermore, SLNB potentially provides even better staging than ALND, as SLNB offers the added benefit of allowing for a more extensive histological analysis of the SNs, by allowing for additional sections through nodes, and by making it possible to use additional immunohistochemical staining methods. These added maneuvers are not routinely performed on nodes obtained from "classical" ALND, since there are too many nodes available for examination from ALND, and testing all of them is not feasible. [22,23].

The role that lymphoscintigraphy (LS) images play in reducing morbidity during SLNB vs. using only the probe without images or using only dye has not been formally examined. Surgeons from ours and other institutions find LS and triangulated body marking (TBM) or other skin marking techniques essential during SLNB [22-26], while others do not find the images or markings helpful [27-29].

Theoretically, an accurate 3-dimensional representation of the number and location of SNs in the body in the form of LS images and TBM reference points or other skin markings, should expedite surgery by allowing a more targeted, minimally invasive approach. This should limit the amount of dissection, and therefore, the level of morbidity. This is an important issue, as the main purpose for performing SLNB is morbidity reduction.

Since no direct studies have investigated the additional reduction in sensory morbidity that LS images and TBM may provide during SLNB, an indirect assessment of this potential was performed by extracting sensory morbidity data on SLNB from studies comparing the morbidity of SLNB to that of ALND [1-20] as described below.

Methods

The computerized bibliographic databases of PubMed and Medline were searched. The key words used in the search included breast, node, and morbidity. In addition, an extensive manual search and cross-referencing from review and original articles was performed. The global inclusion criteria were prospective and retrospective studies that listed any sensory morbidity related to SLNB in breast cancer patients.

Information on study design, lymphoscintigraphy techniques, time of follow-up, and patients' characteristics were collected from the searched articles. When information was not present in the referenced text, personal communications were initiated with the authors to obtain additional information missing from the text; mainly to establish the use or non-use of LS. Based on the information from the articles and personal communications with the authors, 20 articles were found that met these initial criteria [1-20] (Table 1). Three comparisons were made, based on decreasingly stringent levels of comparative parameters described below.

Initial comparisons

For the initial set of comparisons, parameters of morbidity assessment included: 1) pain in the arm or axilla, and 2) numbness on the operated side and/or paresthesias. A subset of the group of 3 studies not using LS were compared to a subset of the 17 studies that used LS. Studies were matched as closely as possible based on the mean time frames of morbidity assessment, to generate best matched time frames of assessing morbidity.

Excluded studies and exclusion criteria for the initial comparisons

The study by Schrenk et al [1] was initially excluded, because SLNB morbidity data were presented for a mixed group of blue dye only and combined dye/radiotracer procedures.

The study by Temple et al [5] was excluded, as a unique morbidity scoring system was employed that could not be adapted in any way for the comparisons. In addition, prevalence data was reported, but the number of patients experiencing symptoms could not be extracted.

One of the two studies by Haid et al [7] was excluded, as no data on the timing of symptom assessment were provided. Symptoms tend to decrease over time, and the time of assessment is needed for any meaningful comparisons.

The study of Ronka et al [16] presented morbidity data which were strictly confined only to the breast, excluding the axilla where SLNB is performed, and therefore was excluded.

Two studies by Rietman et al [12,17], were initially excluded in this constrained comparison because the use of lymphoscintigraphy was unclear [12,17,30-32] and portions of the data in the initial earlier study were in error [12,31,33]. In addition, there are suggestions that a dissection intensive blue dye technique was used as the main method of finding the SN over a more targeted radiotracer/probe method, which appeared to only have a secondary role in finding the SN [12,17,30-32]. These two
studies [12,17] were based on the exact same population of patients but at different time points of morbidity assessment. Yet, the later study [17] fails to acknowledge the existence of the earlier study and its results [12].

Luini A et al [19] presented morbidity data on a mixed group of ALND and SLNB patients where pure SLNB data could not be extracted. The study was therefore excluded.

We also initially excluded additional studies [2,4,10,14,15,18], because pain and numbness and/or paraesthesia morbidity parameters were not assessed at comparable time points to the remaining studies.

For all remaining studies, the criteria for assessing morbidity was chosen as such: either symptoms were present (yes) or absent (no). In studies where a sliding scale of intensity was the method of reporting morbidity symptoms, the percentage of patients fitting into a percent adjusted yes or no group was used [6,20].

After the initial study selection process described above, 7 studies were included in the initial comparative analysis. Among the 7 studies, 5 used LS [8,9,11,13,20] and 2 did not use LS [3,6] (Table 2).

The 7 studies were grouped into the same morbidity category when data was available. Depending on follow-up periods and sensory morbidity assessment techniques, a total of 5 time periods were established.

The resulting comparable time periods of morbidity assessments for pain were ≤1 month, 6 months and 12 to 15.4 months. Likewise, numbness/parasthesia morbidity assessments were at 6 months and 12 to 15.4 months (Table 2).

The statistical analysis was performed using R 2.01 software available in the public domain. Fisher’s exact test was used to analyze the nominal variables in the form of frequency tables. A result was considered to be significant only if the P-value was lower than 0.05. All p-values reported are two-sided.

**Secondary comparisons**

The 20 studies were then reanalyzed with less stringent time of morbidity assessment criteria. Two time periods were created to include the greatest number of studies in the analysis and resulted in the time periods of ≤9 months and >9 months for pain and numbness/parasthesia (Table 3). This allowed the 6 initially excluded studies from table 2 [2,4,10,14,15,18], to be integrated into table 3, resulting in a total of 13 studies included in the secondary comparative analysis. Among the expanded group of 13 studies, 10 used LS [2,4,8-11,13-15,20] and 3 did not use LS [3,6,18] (Table 3). Statistical analysis for Table 3 again utilized Fisher’s exact test.

### Table 1: Studies with data on sensory morbidity and sentinel lymph node biopsy in breast cancer (ref 1-20).

| Reference Year | Journal | Country | Sample Size | Design | Lymphoscintigraphy | Mean Length of Follow-up |
|----------------|---------|---------|-------------|--------|--------------------|--------------------------|
| Schrenk P et al. (1) 2000 | Cancer | Austria | 35 | Prospective | Used | 15.4 M |
| Roumen RM et al. (2) 2001 | Br J Surg | Netherlands | 100 | Prospective | Used | 24 M |
| Burk SE et al. (3) 2002 | Am J Surg | USA | 48 | Prospective | Not Used | 15.4 M |
| Haid A et al. (4) 2002 | Breast Ca Res T | Austria | 57 | Retrospective | Used | 18 M |
| Temple LK et al. (5) 2002 | Ann Surg Oncol | USA | 171 | Prospective | Used | 3 M, 6 M, 12 M |
| Swenson KK et al. (6) 2002 | Ann Surg Oncol | USA | 169 | Prospective | Not Used | 1 M, 6 M, 12 M |
| Haid A et al. (7) 2002 | Eur J Surg Oncol | Austria | 66 | Prospective | Used | Not specified |
| Leidenius M et al. (8) 2003 | Am J Surg | Finland | 49 | Prospective | Used | 2 W |
| Schijven MP et al. (9) 2003 | Eur J Surg Oncol | Netherlands | 180 | Retrospective | Used | 12 M |
| Blanchard DK et al. (10) 2003 | Arch Surg | USA | 685 | Prospective | Used | 2.4 Y |
| Veronesi U et al. (11) 2003 | N Engl J Med | Italy | 100 | Prospective | Used | 6 M, 24 M |
| Rietman J et al. (12) 2003 | Cancer | Netherlands | 66 | Prospective | Used* | 6 W |
| Peintinger F et al. (13) 2003 | Br J Cancer | Austria | 25 | Prospective | Used | 1 W, 9–12 M |
| Baron RH et al. (14) 2004 | Oncol Nurs Forum | USA | 197 | Prospective | Used | 24 M |
| Armer J et al. (15) 2004 | Lymphology | USA | 9 | Retrospective | Used | 9 M |
| Ronka RH et al. (16) 2004 | Acta Oncol | Finland | 57 | Prospective | Used | 12.6 M |
| Rietman J et al. (17) 2004 | Ann Surg Oncol | Netherlands | 66 | Prospective | Used* | 12 M |
| Langer S et al. (18) 2004 | Am Surg | USA | 40 | Retrospective | Not Used | 51 M |
| Luini A et al. (19) 2005 | Breast Ca Res T | Italy | 244 | Prospective | Used | 6–12 M |
| Ronka RH et al. (20) 2005 | Breast | Finland | 43 | Prospective | Used | 12 M |

*Use/method of lymphoscintigraphy unclear, radiotracer used as backup method of finding sentinel node compared to primary dye based technique.
Tertiary comparisons

To further maximize the number of studies compared and be as inclusive as possible, additional studies were integrated into a tertiary analysis by relaxation of criteria. These included the study by Schrenk et al [1], where the heterogeneity of the data set as noted above was overlooked, and the two articles by Rietman et al [12,17], by discounting the issues related to them as noted above and including them in the analysis (Table 4).

Issues with the remaining articles [5,7,16,19] continued to be too significant to be reasonably included in the tertiary comparison, as no meaningful data could be extracted for the reasons already noted above. Statistical analysis for Table 4 again employed Fisher’s exact test.

Among the 20 articles, there were several with similar or partly overlapping patient populations. Specifically the articles of Leidenius M et al [8] and Ronka RH et al [20], as well as Rietman JS et al [12,17] fit this pattern. However, for these articles the times of morbidity assessment were different, so no overlapping of patient populations occurred in any of the comparisons. In one group of articles, Temple et al [5] and Baron RH et al [14], the former was not included in any of the comparisons for reasons already mentioned above, so no overlapping patient populations occurred in any of the comparisons.

### Table 2: Initial comparisons. Comparisons of studies at specific time points that met the constrained criteria detailed in the initial comparison (see text).

| Morbidity       | Mean Length of F/U | Lymphoscintigraphy (+) | Lymphoscintigraphy (-) | p-value |
|-----------------|--------------------|------------------------|------------------------|---------|
|                 | Mor (%) Total Pt (N) References | Mor (%) Total Pt (N) References | |
| Pain            | ≤ 1 m          | 31.08% 74 8,13          | 56.52% 161 6           | 0.0004  |
|                 | 6 m            | 16.00% 100 11           | 37.50% 152 6           | 0.0002  |
|                 | 12–15.4 m     | 11.71% 222 9,20         | 28.67% 143 6           | < 0.0001|
| Numbness/Paresthesia | 6 m        | 2.00% 100 11           | 30.26% 152 6           | < 0.0001|
|                 | 12–15.4 m     | 4.50% 222 9,20         | 22.75% 189 3,6         | < 0.0001|

### Table 3: Secondary comparisons. Comparisons of studies at two time periods that met the criteria detailed in the secondary comparison (see text).

| Morbidity       | Mean Length of F/U | Lymphoscintigraphy (+) | Lymphoscintigraphy (-) | p-value |
|-----------------|--------------------|------------------------|------------------------|---------|
|                 | Mor (%) Total Pt (N) References | Mor (%) Total Pt (N) References | |
| Pain            | Acute (≤ 9 m)     | 22.41% 174 8,11,13     | 47.28%* 161* 6         | < 0.0001|
|                 | Chronic (> 9 m)  | 13.81% 1347 2,4,9,10,11,14,20 | 28.67% 143 6         | < 0.0001|
| Numbness/Paresthesia | Acute (≤ 9 m) | 5.50% 109 11,15        | 35.58%* 160* 6        | < 0.0001|
|                 | Chronic (> 9 m)  | 12.48% 601 4,9,11,13,14,20 | 23.14% 229 3,6,18     | 0.0002  |

* The average morbidity at 1 month and 6 months in article 6. Pain morbidity at 1 month and 6 months are 56.52% (91/161) and 37.50% (57/152), respectively. Numbness/paresthesia morbidity at 1 month and 6 months are 40.63% (65/160) and 30.26% (46/152), respectively.

### Table 4: Tertiary comparisons. Comparisons of studies at two time periods that met the revised (relaxed more encompassing) criteria detailed in the tertiary comparison (see text).

| Morbidity       | Mean Length of F/U | Lymphoscintigraphy (+) | Lymphoscintigraphy (-) | p-value |
|-----------------|--------------------|------------------------|------------------------|---------|
|                 | Mor (%) Total Pt (N) References | Mor (%) Total Pt (N) References | |
| Pain            | Acute (≤ 9 m)     | 22.41% 174 8,11,13     | 47.28%* 161* 6         | < 0.0001|
|                 | Chronic (> 9 m)  | 13.77% 1365 1,2,4,9,10,11,14,20 | 28.67% 143 6         | < 0.0001|
| Numbness/Paresthesia | Acute (≤ 9 m) | 27.43% 175 11,12,15    | 35.58%* 160* 6        | < 0.0001|
|                 | Chronic (> 9 m)  | 12.56% 677 1,4,9,11,13,14,17,20 | 23.14% 229 3,6,18     | 0.1254  |

* The average morbidity at 1 month and 6 months in article 6. Pain morbidity at 1 month and 6 months are 56.52% (91/161) and 37.50% (57/152), respectively. Numbness/paresthesia morbidity at 1 month and 6 months are 40.63% (65/160) and 30.26% (46/152), respectively.

† This comparison remained unchanged from table 3.
population issues occurred when the latter was included in the comparisons. For the studies of Roumen RM et al [2] and Schijven MP et al [9], there potentially appeared to have been very minimal overlap of patient populations. The earlier prospective study [2] had data from 90 patients from one hospital, while the later retrospective study [9] had data on 180 patients from the same hospital as well as another hospital, with the later study [9] data collected mainly outside the timeframe of the earlier study [2]. Correspondence with the author of the earlier study [2] suggested no overlap with independent cohorts. Both studies were therefore included in the analysis.

**Results**

For studies that met the constrained criteria, for all comparison periods, there was less pain and numbness/paresthesia morbidity reported for studies using LS than those that did not, as shown in Table 2. The differences were highly statistically significant (< 0.001). Similar results were obtained in the secondary comparisons, in which the time of morbidity assessment was segregated into two time periods, allowing more studies to be included in the analysis, as shown in Table 3. For the tertiary comparisons in which inclusion criteria were relaxed as described above to maximize the number of studies included, all comparisons showed lower morbidity when LS was used, but only 3 out of 4 were statistically significant (see Table 4). The p-value for the numbness/paresthesia comparison at ≤ 9 months did not reach statistical significance (0.1254). Globally, for the three levels of comparison (Tables 2, 3, 4), all 12 unique comparisons, using various inclusion/exclusion criteria, showed less morbidity for the LS groups. In 11 out of the 12 unique comparisons, the p-values were highly statistically significant (p-value range < 0.0001 to 0.0004). The results for numbness/paresthesia at > 9 months shown in Table 4 are especially pertinent, as this reflects long term outcomes and includes the largest number of patients, and the greatest number of LS and non LS studies.

**Discussion**

The concept that using LS further reduces morbidity over that of using the probe without LS or using dye alone is intriguing to say the least. The analysis we performed suggests that a strong trend exists for additional morbidity reduction in the groups using LS.

The results from this analysis can also be conceptualized from a purely theoretical standpoint; that is: mapping out the location of the SNs in three dimensions prior to incision, knowing the true number of “hot” SNs (or lack of nodes) and the relative intensity and time of appearance to one another should facilitate a targeted surgical approach. Surgeons can plan their approach with this information and adjust their dissection based on the findings of the probe with/without concurrent use of dye.

The results are also supported by the experience of surgeons who have access to high quality LS and skin markings and understand how to use the information. They are of the opinion that both the corresponding images and markings allow for a more directed dissection [23,26].

The studies reviewed in the analysis were not directly trying to evaluate whether LS further reduces morbidity. Had they been, it can be speculated that potentially even better results could have been obtained with LS, especially as the techniques of LS, TBM/skin marking, and SLNB continue to evolve [22-26,34-41], with a renewed focus on accurate anatomical delineation and minimally invasive surgery. In addition, 9 studies that employed LS indicated that they used variable forms of skin marking. Had all studies that employed LS used an updated version of this technique of 3-dimensional SN reference, i.e. TBM, a further morbidity reduction could have potentially been achieved by directing an even more targeted surgical approach [34,36,41].

The greatest limitation of our analysis is that there are only a few studies that did not employ LS (n = 3). Most of the comparisons in the tables were with only a single non LS study [6]. Nevertheless, the results of nearly all comparisons are consistent with results from the specific comparisons that contained 3 non LS studies. The number of studies employing LS was much greater, and provides stable estimates for the proportion having the morbidities of pain and numbness/paresthesias. Because of variations in techniques, time and method of assessing morbidity, direct comparisons between studies are difficult and subject to confounding issues.

The number of nodes removed, use of radiotherapy after SLNB, use of dye in addition to radiotracer, and the harvesting of level III SNs and/or non-axillary nodes could potentially also influence the level of morbidity. These factors were not scrutinized as the information was not consistently available in the referenced articles. For example, information on the biopsy of non-axillary nodes was available only for one reference [8], where 16% (8/49) of SN biopsied were non-axillary. While our study results show an overwhelming advantage for using LS (+) over no LS (-) (essentially a 50% reduction in sensory morbidity at P < 0.0001–0.0003), we are very conservatively describing the results as only a “strong trend” or correlation for the reasons noted above.

Many clinicians dispute any advantages that LS and skin markings may provide in serving the patient during SLNB [27-29,42,43]. The reasons for this could be partly
explained by the great variability in the quality of LS studies that are performed [23,27,28,34-37], and/or perhaps by difficulties on the part of the surgeons in integrating the information provided by LS and skin markings into their surgical techniques during SLNB. Surgical techniques need to be addressed in the pursuit of morbidity reduction. Training tools for surgeons have been developed that have the potential for integrating the information from LS and skin markings, with the goal of performing minimally invasive surgery [38,40].

When the surgeons have a 3-dimensional concept and image of the location of SNs prior to surgery, they are then able to fine tune their surgical approach. An example of this ability to fine tune surgical approach can be applied to a hypothetical case of an upper outer quadrant breast lesion. Initially, the surgeon may plan to attempt to reach the SN via the tumor excision site in an attempt to reduce morbidity. However, when provided with LS images and skin markings the surgeon might realize that this is not the optimal approach from a standpoint of morbidity reduction, and would be able to plan an alternative approach that further minimizes morbidity. It is conceivable that more experienced, better informed surgeons are more likely to utilize LS because of its benefits, and that these surgeons perform a more delicate dissection resulting in less morbidity. However, the exact contribution of LS vs. the skill level of the surgeons that directly contributes to this reduction in morbidity can not be independently deduced from the data in the articles.

Based on this analysis, the surgical evaluation of the sentinel node in the axilla should utilize LS, TBM or other skin marking techniques, and a probe guided dissection in order to reduce sensory morbidity.

**Conclusion**

Though no randomized studies exist that directly ask this question, our literature analysis suggests that lymphoscin-tigraphy imaging is a very useful tool in further reducing morbidity during sentinel lymph node biopsy.

**Competing interests**

The author(s) declare that they have no competing interests.

**Authors' contributions**

CKK contributed to data analysis, design, and preparation of manuscript.

SC contributed to data analysis, design, and preparation of manuscript.

MKS contributed to data analysis, design, and preparation of manuscript.

AT contributed to data analysis, design, and preparation of manuscript.

JM contributed to data analysis, design, and preparation of manuscript.

BRK developed the initial concept and contributed to data analysis, design, and preparation of manuscript.

All authors read and approved the final manuscript.

**References**

1. Schrenk P, Rieger R, Shamiyeh A, Wayand W: Morbidity following sentinel lymph node biopsy versus axillary lymph node dissection for patients with breast carcinoma. Cancer 2000, 88:608-614.

2. Roumen RM, Kuijt GP, Liem IH, van Beek MW: Treatment of 100 patients with sentinel node-negative breast cancer without further axillary dissection. Br J Surg 2001, 88:1639-1643.

3. Burak WE, Hollenbeck ST, Zervos EE, Hock KL, Kemp LC, Young DC: Sentinel lymph node biopsy results in less postoperative morbidity compared with axillary lymph node dissection for breast cancer. Am J Surg 2002, 183:23-27.

4. Haid A, Koberle-Wuhrer R, Knauer M, Burtscher J, Fritzsehe H, Peschina W, Jasaerovic Z, Ammann M, Hergan K, Sturm H, Zimmermann G: Morbidity of breast cancer patients following complete axillary dissection or sentinel node biopsy only: a comparative evaluation. Breast Cancer Res Treat 2002, 73:31-36.

5. Temple LX, Baron R, Cody HS 3rd, Fey JV, Thaler HT, Borgen PI, Hersods AS, Montgomery LL, Petrek JA, Van Zee KJ: Sensory morbidity after sentinel lymph node biopsy and axillary dissection: a prospective study of 233 women. Ann Surg Oncol 2002, 9:655-662.

6. Swenson KK, Nissen MJ, Ceronsky C, Swenson L, Lee MW, Tuttle TM: Comparison of side effects between sentinel lymph node and axillary lymph node dissection for breast cancer. Ann Surg Oncol 2002, 9:745-753.

7. Haid A, Kuehn T, Konstantinuk P, Koberle-Wuhrer R, Knauer M, Kreienberg R, Zimmermann G: Shoulder-arm morbidity following axillary dissection and sentinel node biopsy for breast cancer. Eur J Surg Oncol 2002, 28:705-710.

8. Leidenius M, Leppanen E, Krogerus L, von Smitten K: Motion restriction and axillary web syndrome after sentinel node biopsy and axillary clearance in breast cancer. Am J Surg 2003, 185:127-130.

9. Schijven MP, Vingerhoets AJ, Rutten HJ, Nieuwenhuijzen GA, Roumen RM, van Bussel ME, Voogd AC: Comparison of morbidity between axillary lymph node dissection and sentinel node biopsy. Eur J Surg Oncol 2003, 29:341-350.

10. Blanchard DK, Donohue JH, Reynolds C, Grant CS: Relapse and morbidity in patients undergoing sentinel lymph node biopsy alone or with axillary dissection for breast cancer. Arch Surg 2003, 138:482-487. discussion 487-488.

11. Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V, Intra M, Veronesi P, Roberrson C, Misonneuve P, Reine G, De Cicco C, De Lucia F, Gennari R: A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 2003, 349:546-553.
12. Rietman JS, Dijkstra PU, Geertzen JH, Baas P, De Vries J, Dolsma W, Groothoff JW, Esima WH, Hoekstra HJ: Short-term morbidity of the upper limb after sentinel lymph node biopsy or axillary lymph node dissection for Stage I or II breast carcinoma. Cancer 2003, 98:690-696.

13. Peintinger F, Reitamer S, Strandl H, Ralph G: Comparison of quality of life and arm complaints after axillary lymph node dissection vs sentinel lymph node biopsy in breast cancer patients. Br J Cancer 2003, 89:648-652.

14. Baron RH, Fey JV, Borgen PI, Van Zee KJ: Eighteen sensations after breast cancer surgery: a two-year comparison of sentinel lymph node biopsy and axillary lymph node dissection. Oncol Nurs Forum 2004, 31:691-698.

15. Armer J, Fu MR, Wainstock JM, Zagar E, Jacobs LK: Lymphedema following breast cancer treatment, including sentinel lymph node biopsy. Lymphology 2004, 37:73-91.

16. Ronka RH, Pamilo MS, von Smitten KA, Leidenius MH: Breast lymphedema after breast conserving treatment. Acta Oncol 2004, 43:551-557.

17. Rietman JS, Dijkstra PU, Geertzen JH, Baas P, de Vries J, Dolsma WV, Groothoff JW, Esima WH, Hoekstra HJ: Treatment-related upper limb morbidity 1 year after sentinel lymph node biopsy or axillary lymph node dissection for Stage I or II breast cancer. Ann Surg Oncol 2004, 11:1018-1024.

18. Langer S, Guenther JM, Haigh PI, Difronzo BJ, Zhang ZY, Lippayc H, Machac J: Technical aspects of performing lymphoscintigraphy: optimization of methods used to obtain images. Clin Nucl Med 2000, 25:978-985.

19. Krynyckyi BR, Kim CK, Fedorciw BJ, Zhang ZY, Lipszyc H, Machac J: Areolar-cutaneous "junction" injections to augment sentinel node count activity. Clin Nucl Med 2003, 28:97-107.

20. Krynyckyi BR, Kim CK, Goyenechea MR, Chan PT, Zhang ZY, Machac J: Clinical breast lymphoscintigraphy: optimal techniques for performing studies, image atlas, and analysis of images. Radiographics 2004, 24:121-145.

21. Krynyckyi BR, Sata S, Zolty I, Kim CK, Knesarek K: Reducing exposure from 57Co sources during breast lymphoscintigraphy by optimizing energy windows and other suggested enhancements of acquisition and the display of images. J Nucl Med Technol 2004, 32:198-205.

22. Keshtgar MR, Chicken DW, Waddington WA, Raven W, Ell PJ: A training simulator for sentinel node biopsy in breast cancer: a new standard. Eur J Surg Oncol 2005, 31:134-140.

23. Sugisaka K, Yamamoto T, Sangoku A, Oka M, Kawakami Y, Matsumata N: Sentinel lymph node navigation with three-dimensional interstitial multidetector-row computed tomographic lymphangiography. Invest Radiol 2005, 40:336-342.

24. Krynyckyi BR, Singh G, Colon D, Kim CK, Travis A, Kim SC, Machac J: Letter to the editor [Letter]. Eur J Surg Oncol 2005, 31:805-806.

25. Krynyckyi BR, Kim SC, Kim CK: Preoperative lymphoscintigraphy and triangulated patient body marking are important parts of the sentinel node process in breast cancer. World J Surg Oncol 2005, 3:56.

26. Zografakis TG, Wetherille RE, Christensen RD, Ose KJ, Friedman JD, Colbert M, Svendsen CA, Sanan OK, Tuttle TM: Intraoperative subareolar injection of Tc-99m-labeled sulfur colloid results in consistent sentinel lymph node identification. Ann Surg Oncol 2005, 12:167-172.

27. Lawson LL, Sandler M, Martin W, Beauchamp RD, Kelley MC: Preoperative lymphoscintigraphy and internal mammary sentinel lymph node biopsy do not enhance the accuracy of lymphatic mapping for breast cancer. Am Surg 2004, 70:1050-1055. discussion 1055-1056.